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trauma patients
Introduction 
With the NHS operating under continually tight budgets, efficiency savings are a 
vital part of ongoing financial management. This service evaluation investigates an 
area of potential resource wastage and discusses how this relates to current NHS 
strategies.  
The NHS identified an estimated £30 billion shortfall in its budget and has drawn up 
plans to overturn this deficit by 2021 (Public health England 2014). Although the 
government recently pledged a funding increase of £20.5 billion to manage this 
deficit (Department of health and social care 2018), rising costs mean that revised 
spending strategies will still need to be implemented to capitalise on the benefit of 
the increased budget. One strategy driver highlighted in the NHS 10-point efficiency 
plan is maximising value from the £16 billion spent on drugs each year by the NHS 
by minimising unnecessary wastage (NHS England 2017a). While most of 
expenditure on drugs can be viewed as a necessity, a major study quantifying NHS 
prescribed medication wastage across all areas of healthcare estimated an annual 
cost of £300 million each year (Trueman et al 2010). It has been predicted that there 
is a 3% annual increase in number of prescriptions (Health and social care 
information centre 2016), which would suggest that this figure will have increased 
since these figures were published.  
The government has introduced the Regional Medicines Optimisation Committees 
specifically to focus on whether efficiency savings can be made on a local level 
within existing protocols (NHS England 2017b), although at the time of writing there 
has yet to be information published on the effectiveness of this initiative. Individual 
healthcare Trusts have been tasked with reducing costs by reviewing any existing 
protocols to determine if any efficiency savings can be made. The authors own Trust 
introduced guidelines on the use of chemical thromboprophylaxis in 2016 for 
patients with lower leg injuries which required temporary immobilisation. Its basis 
was to manage the significant risk of venous thromboembolism (VTE), while 
acknowledging 
the relatively low risk of harmful side effects such as bleeding associated with 
thromboprophylaxis treatment. These Trust guidelines standardise practice for this 
patient group but do not discuss potential cost changes associated with this protocol.  
In the UK, the NHS is legally bound to support and fund any protocols recommended 
by the National Institute for Health and Clinical Excellence (Secretary of state for 
health 2013) within a period of three months. NICE review all new treatments in 
terms of both clinical and economic evidence, but while the thromboprophylaxis 
treatment will have been approved in terms of overall cost-effectiveness, there has 
been no analysis into the medication wastage associated with the protocol which 
could highlight areas of potential financial savings. 
This study examines the thromboprophylaxis protocol at the authors own Trust, 
specifically reviewing the extent of medication wastage. The Royal College of 
Emergency Medicine (RCEM) has introduced guidelines on the management of this 
patient group, which underpins Trust policy in the UK (College of emergency 
medicine 2012). RCEM advise that patients should receive daily Clexane for each 
day that their limb remains immobilised, so the Trust uniformly provides 6-week’s 
worth of medication at the time of treatment so ensure the patient does not leave 
with less than the required amount. There is a breadth of published evidence on the 
clinical benefits of this protocol (Nokes and Keenan 2009, Haque et al 2016, Horner 
et al 2020), but this topic has been selected due to the lack of existing data on the 
wastage aspect and the author suggests that improvements in this area could lead to 
significant efficiency savings.  
Objectives 
The primary aim of this audit is to evaluate wastage within the thromboprophylaxis 
protocol and ascertain if and how financial savings can be made, with the proviso 
that patient care is not compromised. Wastage will be defined as 
thromboprophylactic medication that has been provided to the patient for the 
management of their fracture but remains unused and subsequently destroyed at the 
end of treatment. The thromboprophylactic medication used within this protocol is 
Enoxaparin Sodium, known under the brand name Clexane.  
The focussed objectives of this research can be identified as: 
• To ascertain the financial cost to the Trust for each pre-loaded syringe of 
thromboprophylaxis medication. 
• To review patient records over a given time to identify the quantity of 
thromboprophylaxis medication that was unused and thereby disposed of in each 
case.  
• To calculate the total wastage over the duration of the audit and discuss how 
this may reflect on an annual financial saving  
• To discuss potential amendments to service provision in both a local and 
national context that can minimise wastage and improve efficiency.  
 
Design and methods 
This section breaks down the decision-making process and the data gathering 
process into a logical sequence that makes the study theoretically reproducible for 
the reader. 
A pilot study was carried out prior to undertaking this research to determine whether 
there was any likelihood that the study would reveal any significant wastage within 
the current protocol. This would determine if there was a potential need for change 
or improvement and serve as justification to proceed with this audit.  
The results of this pilot showed significant wastage in medication with just over 30% 
of the prescribed Clexane being used as intended, with the remainder returned and 
destroyed. National policy states that any medication returned from patients should 
not be reused to avoid the risk that it has been stored incorrectly which can 
compromise medication effectiveness (Royal pharmaceutical society 2016). This 
means that unused medication can be interpreted directly as wastage of resources. 
As a result of these findings the full study proceeded to quantify the amount of 
wastage by using a much larger sample size and also to determine a financial value 
to this wastage.  
This study analysed retrospective data for all patients meeting the eligibility criteria 
detailed below, over a six-month period to create a sample set of data which could 
be used to evaluate the aims and objectives. The author chose this method in 
preference to a prospective study to ensure that the data collection could be 
completed in sufficient time to allow analysis and review within the given timeframe. 
Using retrospective data also minimises the potential bias of clinical practice being 
modified as the result of the study (Santos-Eggimann et al 1997). No patients were 
involved in the process and there was no impact on patient care. The study is 
deemed an audit as it reviews the performance of an initiative within a single Trust 
rather than researching the effects and impact of a clinical treatment across wider 
healthcare (Healthcare quality improvement partnership 2011). All data gathering 
was carried out by the author to ensure that a universal standard of information 
processing was used across all records and to avoid data collection bias.  
This audit was focussed on the A&E department of the authors own NHS Trust. The 
study generated a comprehensive list of patients initiated on to the Clexane 
treatment pathway within a specified time and was estimated in advance to include 
30-50 eligible patients. This number was based on estimates from the orthopaedic 
consultant who routinely manages these patients, considering the mean number of 
Clexane patients they would expect to observe over any random 6-month period.   
Study design 
This service evaluation was a solely quantitative study that drew data from the 
patient records relating to the usage and wastage of Clexane. Potential sources of 
bias within the study were minimised by consideration of the following factors: 
• Use of retrospective data ensured that the study did not influence clinical 
practice 
• All data collection was carried out by the author. This ensured uniformity in 
the application of inclusion and exclusion criteria 
• Data was collected over a sufficient period to ensure that it was representative 
of ongoing practice 
• The criteria used to select participants in the sample was stated precisely. 
These criteria were adhered to objectively throughout the study 
• Any problems with the data collection process or unexpected findings were 
commented on as part of the results to ensure transparency  
All information was stored securely to ensure patient confidentiality and information 
governance was adhered to always (McSherry and Pearce 2011). Patient data was 
encrypted before it was removed from the hospital grounds and was only published 
in the finished audit once it had been fully anonymised. Care was taken at the time of 
planning to ensure that ethical regulations were adhered to and patient care was not 
compromised throughout. The study was carried out with the approval of the Trust 
research and development team. 
Inclusion and exclusion criteria 
The timeframe for eligibility to this study was patients who had their treatment 
initiated between 1st July 2017 to 31st December 2017 inclusive. It was considered 
that with the protocol launching in 2016 there may have been an initially reduced 
uptake on the treatment pathway, so a more current data set may provide a better 
indication of the usage of the treatment pathway. The data window would finish at 
the end of 2017 to allow enough time for the gathering and analysis of the 
information. 
This research aims to include all patients who have sustained a lower leg fracture, 
and have had their risk of thrombosis managed by the initiation of Clexane therapy 
by the attending clinician. The following list highlights any patient groups that will be 
excluded from the final data set. Any data points that represent outlying values will 
be commented on individually but still included in the results. 
• Patients with clinical management transferred outside of the Trust 
• Patients admitted for open surgery. (Patients managed by closed reduction 
can still be included) 
• Significant comorbidities or multiple injuries which impacts on treatment with 
routine chemical thromboprophylaxis. 
• Insufficient data to review management 
Collection of data 
A list of potential target patients was generated by using specific indicators to refine 
the search within the time frame. All ineligible patients would then be excluded, with 
a reason noted for their omission and the remaining list would then be considered as 
the sample group. The outcomes for each of these patients would then be reviewed 
to determine the date on which the patient was remobilised and Clexane treatment 
was stopped. The number of doses of Clexane used was calculated on the 
assumption that one dose was used for each day of treatment, including the final day 
when the treatment was stopped. The number of unused Clexane doses was 
calculated by subtracting the number of used doses from the number of prescribed 
doses, which is set at 42 by the Trust policy.  
Problems encountered 
The main problems throughout the process involved the Trusts usage of paper 
records rather than using an electronic system database, as the Trust’s archives had 
organisational flaws which meant that some records were misplaced or misfiled. In 
each case the file is no longer obtainable so is not able to be used for further 
reference. Missing records can be detrimental to patient care as there could 
potentially be important clinical information in these records which is consequently 
not acted upon. Although studies have shown that paper record systems can have 
some advantages over electronic databases, it is dependent on user diligence 
(Stausberg et al 2003) which in this case led to lost data. As this point can be 
considered a risk factor to patient safety a Datix would be completed to report this in 
a formal way and ensure that follow up measures would be taken at the next 
opportunity.  
Identifying the target records for this research relies on the accurate coding of each 
case by the clinician at the time of entry. Any records that had the wrong coding 
entered by mistake would also be almost impossible to locate by a subject search 
like this due to the volume of patients that pass through the department. 
There is no data available regarding patient compliance to medication, so any 
missed doses would not be detected. If this occurs, these cases will represent a 
higher level of wastage than recorded by the author. As this exact data is not 
available, this study will assume that one dose is taken on each day of treatment, but 
the author acknowledges that this leaves room for a small margin of discrepancy in 
the results.  
Results, findings and outcomes 
The initial phase of data gathering identified a list of 207 patients coded for a lower 
leg fracture within the time window. These cases were reviewed to determine 
whether the patient was treated under the thromboprophylaxis protocol. Graph 1 
highlights the outcomes of each of these patient encounters providing an overview of 
the reasons why potentially suitable patients might not be treated under the 
thromboprophylaxis protocol.  
Graph 1 – Interpretation of patient outcomes within study group 
 Of the data set of 207 patients with lower leg fractures, 20 of these were eligible for 
the audit and were discharged from hospital with the Clexane thromboprophylaxis 
protocol. Of these patients, 2 were omitted at this stage as they met the exclusion 
criteria. The remaining 18 cases are displayed in Table 2 along with any relevant 
case notes, with this list comprising the final study group for analysis. All patient 
indicators were removed to ensure no breach in confidentiality. The table includes 
the number of wasted doses calculated on the basis that each patient is provided 
with 42 doses of Clexane as per protocol and that a dose was used on each day 
while they were managing their own treatment in the community.  
Table 2 – Review of wasted medication  
# Number of 
wasted 
doses 
(Syringes) 
Relevant case notes 
1 39  
2 37  
3 36 Commenced Clexane 3 days earlier due to injury while abroad. 
Further medication provided and referred to fracture clinic at first 
attendance with Trust 
4 32 Commenced Clexane 5 days earlier due to injury while abroad. 
Further medication provided and referred to fracture clinic at first 
attendance with Trust 
5 33  
6 31  
10% - Discharged 
with Clexane 
treatment
20/207 patients
1% - Declined 
further treatment
3/207 patients
30% - Record 
Unavailable
62/207 patients
4% - No acute 
fracture noted
8/207 patients
39% -
Thromboprophylaxis not 
required
81/207 patients
1% - Not treated 
when indicated
2/207 patients
15% - Admitted to 
hospital
31/207 patients
Patient Outcomes
7 22 Commenced Clexane 3 days earlier due to injury while abroad. 
Further medication provided and referred to fracture clinic at first 
attendance with Trust 
8 20  
9 33  
10 0 Advised by consultant after 27 days to remove rigid cast and stop 
Clexane. Patient rejected this so agreed to remain on the treatment 
protocol for a further two weeks 
11 33  
12 8 Sustained injury 10 days prior to attendance. Clexane treatment 
commenced abroad, initial attendance was for further medication 
only; fracture management plan already in place 
13 32  
14 34  
15 31  
16 22 Clexane treatment stopped at patient discretion against medical 
advice.  
Replaced with oral anticoagulants 
17 3  
18 3  
Total 449  
Mean  24.9  
 
Additional findings showed that all but one of these consultations occur within 2 
weeks of the initial attendance. There was limited information on the outlier result 
regarding why the patient was not followed up until day 30 other than that the 
management plan was initiated outside of the Trust. 
Trust policy is that each patient is contacted directly on the next working day and the 
review of records showed that all but one case was contacted within 4 days of their 
initial attendance. This demonstrates that the cases are routinely reviewed at the 
earliest opportunity to allow maximum time to resolve any potential problems in 
clinical management.  
The results show an overall degree of wastage for the patient group initiated onto the 
treatment program over the course of the study period. Of the 756 syringes were 
distributed cumulatively to the sample group, 449 of these doses remained unused 
representing 59% of medication units that must be returned and destroyed. 
There are only 5 patients out of the sample of 18 that used at least half of their initial 
supply of medication as shown in graph 3. 
 
Graph 3 – Medication wastage for each patient 
 
Cost implications 
Determining a cost value for the wasted doses proved difficult as the price of 
medication varies over time under the influence of supply and demand. Costing 
details for any given batch of medication is not readily available so for the purpose of 
the study a representative value was used.  
The published cost per syringe when the protocol was launched was £9.77 (National 
Institute for Health and Care Excellence 2015) while publicly available costing data 
at the time of study showed a unit cost of £3.03 (National Institute for Health and 
Care Excellence 2018). This made the total cost of wastage for the duration of the 
study £4,386.73, or £1,360.47 depending on which price structure was used. These 
findings infer a 69% drop in costing since the protocol was launched. 
Discussion 
The data collected throughout the course of this project has been analysed and can 
be used as a sample of a wider population. In a protocol that has been widely 
accepted for its clinical benefits and the money it consequently saves the healthcare 
service, this service evaluation has identified an aspect of it that clearly 
demonstrates avoidable financial waste. 
In a protocol such as this there will always be a degree of medication wastage as 
there must be a margin of tolerance to minimise the risk of missed doses. However, 
this study has identified the level of wasted medication at 59% of the amount initially 
distributed which the author would suggest is unacceptably high, especially if this 
wastage is avoidable. Due to the lack of published financial information in this field it 
is likely that there is not much awareness of this situation, but the data shows that 
relevant savings that can be made if this wastage is reduced. 
The difficulty obtaining accurate pricing is acknowledged as a minor weakness in the 
study, although efforts were made to use the most accurate representative values. 
While the findings highlight how the cost efficiency of a new medication protocol can 
improve dramatically during the initial period, it is difficult to accurately evaluate a 
service without clarity in the financial data. The cost of medication will be easier to 
determine in future as the cost of LMWH will become more stable the longer it has 
been on the market. A repeat of this audit at a future date would yield more accurate 
financial findings.  
The author would state however that these values are likely to be highly indicative of 
the true amounts and are appropriate for the purposes of this study in an 
assessment of the financial wastage. The data in this project shows that the main 
factor in reducing financial wastage has been this fall in costs, rather than the 
numerical value of any wastage. While these costs do have potential to fall further, 
as studies show that after the launch phase of a new product on the market, follow-
on drugs induce price competition (Mueller and Frenzel 2015). However, these 
prices would tend to level out as the Clexane product becomes well established and 
pricing becomes driven by market values (Stevenson et al 2017). However, while an 
accurate review of costs will enable a Trust to quantify the level of financial wastage, 
any wastage that can be considered avoidable can be targeted as a means of 
reducing costs which is currently a priority for any Trust. 
Proposed change to practice 
The study suggests that the main factor behind the medication wastage within this 
protocol is the over-dispensing of medication at the point of discharge, so this area 
could be targeted for potential efficiency savings. The author would suggest an initial 
supply of Clexane doses be provided for a period of two weeks rather than six. As 
RCEM guidelines requires treatment to continue for the duration of the limb 
immobilisation (College of emergency medicine 2012), further medication could 
either be given when they attend their fracture clinic review, or the patient could be 
provided with a dated prescription for further doses when they are first treated which 
can be redeemed at the pharmacy only if appropriate. As the patient is considered 
ambulatory on discharge it should be possible for them to attend a pharmacy in the 
same manner that they are required to attend fracture clinic, but if there are 
extenuating circumstances why this is not possible the clinician can incorporate this 
into the management plan at their discretion to ensure there is no increased risk of 
doses being missed. Provided the patient has the theory and practicalities of the 
process explained to them clearly and is given the means carry out the process, the 
responsibility of implementation then lies with the patient. The author believes that 
these proposed changes would not represent an increased risk to patient health, with 
the healthcare provider still available in a supporting capacity if any problems with 
committing to the treatment arose. The Trust must be seen to conform to the national 
guidelines in this area to avoid potential litigation if any complications arise, but the 
author believes that these changes still operate within the framework of the 
published guidelines and do not represent a deviation from best clinical practice.  
If the proposed reduction in medication was introduced before this service 
evaluation, the number of wasted doses would be reduced from 449 doses to 99 
doses. As a percentage this sees the level of wastage fall from 59% to 13%. While 
there is no framework for determining what an acceptable level of wastage is, this 
represents a significant improvement in efficiency savings which would be appealing 
to any healthcare provider.  
Using the costing figures from 2017 this would represent a financial saving of 
£1,060.50 over the six-month period that the research covered. Extrapolating this 
figure to give an annual cost would suggest estimated savings to the Trust of over 
£2,000. While the figure is not high in relation to NHS budgets, when it is considered 
across the entire healthcare system where there are 195 Clinical Commissioning 
Groups with most containing more than one acute treatment (NHS Clinical 
commissioners 2018), this amount is likely to be a considerable six figure sum that is 
wasted each year. Taking into account the many minor injury units and urgent care 
centres now utilising this treatment pathway as well, the author uses these values to 
project potential savings to the NHS of up to £500,000 per year. This figure is 
significant when considered in the context of the NHS efficiency strategies discussed 
earlier that look to minimise unnecessary wastage (NHS England 2017b). While 
most of this amount can be viewed as necessary expenditure, an estimated saving 
of 3-5% from this figure would represent an important positive move for cost 
effectiveness. If any improvements can be made at the authors own Trust on a pilot 
basis, these advantages can then be utilised by other Trusts across the country to 
maximise the benefits.  
 
The study also showed that barring mitigating circumstances, the Trust was effective 
in following up referrals efficiently, as patients were routinely contacted within 3 days 
of initial presentation, with a review in clinic within 2 weeks of presentation. Guidance 
published by the British Orthopaedic Association recommends that all referred 
patients referred should be seen in fracture clinic within 72 hours of initial 
presentation (British orthopaedic association 2014), meaning Clexane doses for 2 
weeks would certainly provide the patient with enough medication. If there are any 
foreseeable reasons at the point of discharge that may prevent the patient being 
reviewed within these recommended timescales, it would be advisable to discharge 
with a greater amount of medication to reduce the risk of the patient running out of 
doses.  
 
Conclusion 
This audit has investigated the level of discarded medication within the 
thromboprophylaxis protocol and explored how changes can be made to minimise 
this wastage. By analysing patient data over a six-month period, the study has 
shown that 59% of the medication that is distributed to the patient at the point of 
treatment is unused and ultimately destroyed. While a degree of wastage is 
inevitable the author would suggest that this is higher than an acceptable level and 
would recommend measures to reduce this. 
The primary recommendation of this study is to reduce the amount of Clexane 
distributed to the patient from 6-weeks’ worth of medication to 2-weeks’ worth of 
medication. The author anticipates this would have no significant detrimental effect 
on patient care or safety. The findings from this study suggest that implementing 
these proposed changes could reduce the amount of medication wastage to just 
13% of the amount distributed. With a potential financial saving of up to £500,000 
annually without any cost of implementing a change the benefits are clear, so the 
subject would warrant further consideration. 
With limited existing research into medication wastage in these protocols, the author 
would advocate trialling the recommendations from this review at other Trusts in the 
UK to see if these findings could be reproduced. If improvements in efficiency and 
financial performance can be confirmed, the author recommends implementation of 
these proposals in any comparable healthcare settings.  
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